openPR Logo
Press release

Osteoporosis Pipeline Drugs in 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, and Route of Administration by DelveInsight Featuring Novadip, Eli Lilly, Teva Pharmaceuticals, Novartis, Amgen, USB, Gedeon Richter Plc., Luye Pharma

01-12-2024 06:40 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Osteoporosis Pipeline

Osteoporosis Pipeline

(Las Vegas, Nevada, United States) Delve into the intricate landscape of Osteoporosis clinical research with DelveInsight's latest report, providing a thorough examination of 30+ leading Osteoporosis companies actively engaged in developing over 40 Osteoporosis treatment therapies. This comprehensive insight into Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments positions DelveInsight at the forefront of Osteoporosis pipeline analysis.

Uncover the Current Osteoporosis Clinical Development Scenario and Growth Prospects across the Osteoporosis Market through the lens of DelveInsight's "Osteoporosis Pipeline Insight, 2023" report. This report not only delivers in-depth commercial and clinical assessments but also spans the entire developmental spectrum, from pre-clinical phases to the marketed phase.

Dive into detailed descriptions of each drug, encompassing their mechanisms of action, clinical studies, NDA approvals (if any), and a comprehensive overview of product development activities. The report goes beyond, exploring technological aspects, collaborations, mergers and acquisitions, funding details, designations, and other crucial product-related information. Stay ahead with DelveInsight's unparalleled insights into the dynamic Osteoporosis Pipeline.

Some of the key takeaways from the Osteoporosis Pipeline Report: https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Companies across the globe are diligently working toward developing novel Osteoporosis treatment therapies with a considerable amount of success over the years.
• Osteoporosis companies working in the treatment market are Lactocore, Rani Therapeutics, Jiangsu HengRui Medicine, Entera Bio, Levolta Pharmaceuticals, Inc., Celltrion, Teva Pharmaceuticals, Novartis, Amgen/USB, Gedeon Richter Plc., Luye Pharma, Haoma Medica, and others, are developing therapies for the Osteoporosis treatment
• Emerging Osteoporosis therapies in the different phases of clinical trials are- Research programme, RT-102, SHR-1222, EB613, VOLT01, CT-P41, TVB-009, Zoledronic Acid, Romosozumab, RGB-14-P, Denosumab biosimilar, NaQuinate, and others are expected to have a significant impact on the Osteoporosis market in the coming years.
• The "A Randomised, Double-Blind, Multinational, Multicenter Study to Compare Efficacy, Safety, and Immunogenicity of TVB-009P and Denosumab (Prolia®) in Patients With Postmenopausal Osteoporosis" was started by Teva Pharmaceuticals in March 2023.

Osteoporosis Overview
Osteoporosis is a condition in which the density of bone decreases, weakening it and making it more brittle. Osteoporosis causes bone to become deformable and unusually porous, much like a sponge. This skeletal condition makes the bones weaker and makes them more prone to fractures (breaks).

Get a Free Sample PDF Report to know more about Osteoporosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Osteoporosis Drugs Under Different Phases of Clinical Development Include:
• Research programme: Lactocore
• RT-102: Rani Therapeutics
• SHR-1222: Jiangsu HengRui Medicine
• EB613: Entera Bio
• VOLT01: Levolta Pharmaceuticals, Inc.
• CT-P41: Celltrion
• TVB-009: Teva Pharmaceuticals
• Zoledronic Acid: Novartis
• Romosozumab: Amgen/USB
• RGB-14-P: Gedeon Richter Plc.
• Denosumab biosimilar: Luye Pharma
• NaQuinate: Haoma Medica
• JMT 103: Shanghai JMT-Bio Inc.
• TST-002: Transcenta Holding

Osteoporosis Route of Administration
Osteoporosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Osteoporosis Molecule Type
Osteoporosis Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule

Osteoporosis Pipeline Therapeutics Assessment
• Osteoporosis Assessment by Product Type
• Osteoporosis By Stage and Product Type
• Osteoporosis Assessment by Route of Administration
• Osteoporosis By Stage and Route of Administration
• Osteoporosis Assessment by Molecule Type
• Osteoporosis by Stage and Molecule Type

DelveInsight's Osteoporosis Report covers around 40+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Osteoporosis product details are provided in the report. Download the Osteoporosis pipeline report to learn more about the emerging Osteoporosis therapies at:
https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Osteoporosis Therapeutics Market include:
Key companies developing therapies for Osteoporosis are - Shanghai Biomabs Pharmaceutical, Angitia Biopharmaceuticals, Dongkook pharmaceutical, Biocon Biologics UK Ltd, Bonus BioGroup Ltd., Cellatoz Therapeutics, Inc., Keros Therapeutics, Clayton Biotechnologies, Novadip, Eli Lilly, Teva Pharmaceuticals, Novartis, Amgen, USB, Gedeon Richter Plc., Luye Pharma, Haoma Medica, Jiangsu HengRui Medicine, Shanghai JMT-Bio Inc., Transcenta Holding, Celltrion, Enzene Biosciences, Fresenius Kabi, Gedeon Richter, Samsung Bioepis, Alvotech, MAbxience, Shanghai Henlius Biotech, Rani therapeutics, Entera Bio, Paras Biopharmaceuticals, Shenzhen Salubris Pharmaceutical, Enteris Biopharma, Prestige Biopharma, Shinpoong Ltd., and others.

Osteoporosis Pipeline Analysis:
The Osteoporosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Osteoporosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Osteoporosis Treatment.
• Osteoporosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Osteoporosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Osteoporosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Osteoporosis drugs and therapies-
https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Osteoporosis Pipeline Market Drivers
Rising geriatric population prone to low bone density, growing investments in research and development, increased Focus on development of biosimilars for the treatment of Osteoporosis are some of the important factors that are fueling the Osteoporosis Market.

Osteoporosis Pipeline Market Barriers
• However, side effects and complications associated with osteoporosis drugs, patent expiration of osteoporosis drugs and other factors are creating obstacles in the Osteoporosis Market growth.

Scope of Osteoporosis Pipeline Drug Insight
• Coverage: Global
• Key Osteoporosis Companies: Lactocore, Rani Therapeutics, Jiangsu HengRui Medicine, Entera Bio, Levolta Pharmaceuticals, Inc., Celltrion, Teva Pharmaceuticals, Novartis, Amgen/USB, Gedeon Richter Plc., Luye Pharma, Haoma Medica, and others
• Key Osteoporosis Therapies: Research programme, RT-102, SHR-1222, EB613, VOLT01, CT-P41, TVB-009, Zoledronic Acid, Romosozumab, RGB-14-P, Denosumab biosimilar, NaQuinate, and others
• Osteoporosis Therapeutic Assessment: Osteoporosis current marketed and Osteoporosis emerging therapies
• Osteoporosis Market Dynamics: Osteoporosis market drivers and Osteoporosis market barriers

Request for Sample PDF Report for Osteoporosis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/osteoporosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Osteoporosis Report Introduction
2. Osteoporosis Executive Summary
3. Osteoporosis Overview
4. Osteoporosis- Analytical Perspective In-depth Commercial Assessment
5. Osteoporosis Pipeline Therapeutics
6. Osteoporosis Late Stage Products (Phase II/III)
7. Osteoporosis Mid Stage Products (Phase II)
8. Osteoporosis Early Stage Products (Phase I)
9. Osteoporosis Preclinical Stage Products
10. Osteoporosis Therapeutics Assessment
11. Osteoporosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Osteoporosis Key Companies
14. Osteoporosis Key Products
15. Osteoporosis Unmet Needs
16 . Osteoporosis Market Drivers and Barriers
17. Osteoporosis Future Perspectives and Conclusion
18. Osteoporosis Analyst Views
19. Appendix
20. About DelveInsight

Latest Reports launched by DelveInsight:
• Foot And Ankle Devices Market: https://www.delveinsight.com/report-store/foot-and-ankle-devices-market
• Hepatitis B Virus Market: https://www.delveinsight.com/infographics/chronic-hepatitis-b-virus-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Alopecia Aerata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Brain/cranial Implants Market: https://www.delveinsight.com/report-store/brain-implants-market-market
• Global Electrophysiology Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Hemodynamic Monitoring Systems Market: https://www.delveinsight.com/report-store/hemodynamic-monitoring-system-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Parkinson's Disease Market: https://www.delveinsight.com/report-store/parkinsons-disease-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Scleroderma Market: https://www.delveinsight.com/report-store/scleroderma-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Hyperuricemia Market: https://www.delveinsight.com/report-store/hyperuricemia-pipeline-insight
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market

Contact Us:
Ankit Nigam
Assistant Manager Marketing
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Osteoporosis Pipeline Drugs in 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, and Route of Administration by DelveInsight Featuring Novadip, Eli Lilly, Teva Pharmaceuticals, Novartis, Amgen, USB, Gedeon Richter Plc., Luye Pharma here

News-ID: 3350097 • Views:

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides

All 5 Releases


More Releases for Osteoporosis

Rising Prevalence Of Osteoporosis Fuels Growth In The Osteoporosis Drug Market: …
The Osteoporosis Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Osteoporosis Drugs Market Size During the Forecast Period? The market for medications for osteoporosis has seen a consistent rise in recent years. The current market value of $12.33 billion in 2024
Rising Prevalence Of Osteoporosis Spurs Momentum In Postmenopausal Osteoporosis …
The Postmenopausal Osteoporosis Treatment Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Current Postmenopausal Osteoporosis Treatment Market Size and Its Estimated Growth Rate? The market for treatment of postmenopausal osteoporosis has seen a steady increase in size over the recent years. It's projected
Osteoporosis Drug Market, By Type (Primary Osteoporosis and Secondary Osteoporos …
Osteoporosis is a condition of bone weakening or bones becomes fragile and likely to break. In other words, osteoporosis is a condition wherein the bone density decreases. This is specially witnessed in old age people. Osteoporosis brings along back pain, stooped posture, bone fracture and tooth loss. View Detailed Report" https://www.databridgemarketresearch.com/reports/global-osteoporosis-drug-market The global osteoporosis drug market is experiencing steady growth driven by factors such as the increasing aging population, rising prevalence of
Osteoporosis Drugs: The Complete Review
Medication for osteoporosis increases bone mineral density and reduces fracture risk. Some osteoporosis medications promote bone growth while others reduce bone loss. The bones may begin to deteriorate as age more quickly than the body can heal them. The doctor could determine that people have osteoporosis if they have significant bone density loss. To receive free sample pages of this report@ https://www.psmarketresearch.com/market-analysis/osteoporosis-drugs-market/report-sample Although osteoporosis cannot be treated, it can be slowed down or
Osteoporosis Drugs Market: Demand for Osteoporosis Drugs High Among Geriatric Po …
The global osteoporosis drugs market is analyzed in a report by Transparency Market Research (TMR). The market is expected to grow due to the increasing geriatric population across the globe. The market for osteoporosis drugs is considered semi-consolidated as a handful of players hold a larger share in the market. As per the analysis, Novartis International AG, Eli Lilly and Company, Merck & Co. Inc., Pfizer Inc., and Amgen Inc.
Global Postmenopausal Osteoporosis Therapeutics Market
The Postmenopausal Osteoporosis Therapeutics Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. Osteoporosis is an orthopedic condition where the bone density and bone mass decreases and eventually increases the risk of bone fracture. Osteoporosis is one of the most common age related